Keensight Capital is to invest alongside management in Axxam, a innovative Partner Research Organization (iPRO) in the life sciences industry. The deal will see the private equity manager acquire a majority stake in Axxam from the current shareholders, including Bayer SpA and Zambon Company SpA.
Axxam, headquartered in Milan (Italy), employs around 180 people, most of whom have received PhDs in life sciences related disciplines. The Company is one of the largest biology-centric organisations, providing research services to major life sciences companies around the globe.
Keensight Capital intends to support the management team, led by the two co-founders Dr Stefan Lohmer and Dr Alessandro Sidoli, as well as chief financial officer Luigi Gavazzeni, in pursuing and accelerating the growth of the Company to realise its significant potential.
